Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C

Bibliographic Details
Main Author: Paraná, Raymundo
Publication Date: 2006
Other Authors: Schinoni, Maria Isabel, Freitas, Luiz Antonio Rodrigues de, Codes, Liana, Cruz, Marla, Andrade, Zilton de Araújo, Trépo, Christian
Format: Article
Language: eng
Source: Repositório Institucional da FIOCRUZ (ARCA)
DOI: 10.1111/j.1478-3231.2006.01345.x
Download full: https://arca.fiocruz.br/handle/icict/7858
Summary: Faculty of Medicine University Hospital of Bahia. Gastro-Hepatology Unit. Salvador, BA, Brasil
id CRUZ_17f3c6227f559a67c848ce63d2b42f02
oai_identifier_str oai:arca.fiocruz.br:icict/7858
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Paraná, RaymundoSchinoni, Maria IsabelFreitas, Luiz Antonio Rodrigues deCodes, LianaCruz, MarlaAndrade, Zilton de AraújoTrépo, Christian2014-06-30T18:39:42Z2014-06-30T18:39:42Z2006PARANÁ, R. et al. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver International, v. 26, p. 1148-1154, 2006.1478-3223https://arca.fiocruz.br/handle/icict/785810.1111/j.1478-3231.2006.01345.xengBlackwell MunksgaardAnti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis Cinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFaculty of Medicine University Hospital of Bahia. Gastro-Hepatology Unit. Salvador, BA, BrasilFederal University of Bahia. Post Graduated Program on Medicine and Health Faculty of Medicine. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, BrasilFederal University of Bahia. Post Graduated Program on Medicine and Health Faculty of Medicine. Salvador, BA, BrasilLEME Laboratory. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, BrasilINSERM_U. University Claude Bernard. Lyon, FranceBackground/Aim: Pegylated interferon (Peg-IFN) plus ribavirin is the standard therapy for hepatitis C. Peg-IFN has several antiviral mechanisms, but its role in hepatitis C treatment seems to be related to its immunomodulatory effect. Ribavirin, an antiviral agent, potentiates IFN activity when added to it. Both drugs are associated with adverse reactions of different magnitudes. Autoimmune phenomena have been reported with this treatment. In this paper, we describe cases of ALT/GGT flares during Peg- IFN plus ribavirin treatment, which related to the appearance of anti-Golgi antibody and disease progress. Methods: We investigated three patients with hepatitis C and severe ALT/GGT flares during Peg-IFN and ribavirin treatment coinciding with anti-Golgi complex antibody as the only marker of autoimmunity. We then reviewed the medical files and tested anti-Golgi antibody in stored sera from 25 patients treated with conventional IFN and in 14 patients treated with Peg-IFN. Results: The three patients were male, over 45 years of age; all were relapsers and non-responders. Anti-Golgi antibody was positive during treatment coinciding with ALT/GGT flares but with hepatitis C virus (HCV)-RNA negativity, disappearing after stopping treatment, with normalization of ALT/AST levels. One patient had progression of fibrosis from F2 to F3 despite negativity of HCV-RNA. In the last group, only two patients treated with Peg-IFN experienced ALT/GGT flares but without anti-Golgi antibody Conclusions: The presence of anti- Golgi complex antibody could be a marker of a temporary autoimmune phenomenon and progressive disease.Antivirais/efeitos adversosAutoanticorpos/sangueComplexo de Golgi/imunologiaHepatite C/sangueHepatite C/quimioterapiaInterferon-alfa/efeitos adversosPolietilenoglicóis/efeitos adversosRibavirina/efeitos adversosAlanina Transaminase/sangueAntivirais/uso terapêuticoProgressão da DoençaQuimioterapia CombinadaHepacivirus/genéticaInterferon-alfa/uso terapêuticoHumanosFígado/patologiaCirrose Hepática/patologiaPolietilenoglicóis/uso terapêuticoMasculinoMeia-IdadeProteínas RecombinantesRibavirina/uso terapêuticoinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZORIGINALPArana R Anti-golgi....pdfPArana R Anti-golgi....pdfapplication/pdf597871https://arca.fiocruz.br/bitstreams/efe7338f-e2ba-49a9-86a9-1ebefd219bfc/downloadcaa0974b7b405828343650aa19017da3MD51trueAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81914https://arca.fiocruz.br/bitstreams/30e8dbe5-35b3-4c1a-aa2f-8e90ec5f5e57/download7d48279ffeed55da8dfe2f8e81f3b81fMD52falseAnonymousREADTEXTPArana R Anti-golgi....pdf.txtPArana R Anti-golgi....pdf.txtExtracted texttext/plain25897https://arca.fiocruz.br/bitstreams/e24d1540-02d9-418e-ad22-b9b0534b6cd4/download771fa2a068b1125bf61ec3866e51f1e8MD55falseAnonymousREADTHUMBNAILPArana R Anti-golgi....pdf.jpgPArana R Anti-golgi....pdf.jpgGenerated Thumbnailimage/jpeg6215https://arca.fiocruz.br/bitstreams/435c7030-ece3-4f29-9e61-1f95a9d6676c/downloadf5a20b37ce866f1c702e27e8adf42dd2MD56falseAnonymousREADicict/78582025-07-30 02:07:04.26open.accessoai:arca.fiocruz.br:icict/7858https://arca.fiocruz.brRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352025-07-30T05:07:04Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)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
dc.title.none.fl_str_mv Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
title Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
spellingShingle Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
Paraná, Raymundo
Antivirais/efeitos adversos
Autoanticorpos/sangue
Complexo de Golgi/imunologia
Hepatite C/sangue
Hepatite C/quimioterapia
Interferon-alfa/efeitos adversos
Polietilenoglicóis/efeitos adversos
Ribavirina/efeitos adversos
Alanina Transaminase/sangue
Antivirais/uso terapêutico
Progressão da Doença
Quimioterapia Combinada
Hepacivirus/genética
Interferon-alfa/uso terapêutico
Humanos
Fígado/patologia
Cirrose Hepática/patologia
Polietilenoglicóis/uso terapêutico
Masculino
Meia-Idade
Proteínas Recombinantes
Ribavirina/uso terapêutico
title_short Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
title_full Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
title_fullStr Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
title_full_unstemmed Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
title_sort Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
author Paraná, Raymundo
author_facet Paraná, Raymundo
Schinoni, Maria Isabel
Freitas, Luiz Antonio Rodrigues de
Codes, Liana
Cruz, Marla
Andrade, Zilton de Araújo
Trépo, Christian
author_role author
author2 Schinoni, Maria Isabel
Freitas, Luiz Antonio Rodrigues de
Codes, Liana
Cruz, Marla
Andrade, Zilton de Araújo
Trépo, Christian
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Paraná, Raymundo
Schinoni, Maria Isabel
Freitas, Luiz Antonio Rodrigues de
Codes, Liana
Cruz, Marla
Andrade, Zilton de Araújo
Trépo, Christian
dc.subject.decs.none.fl_str_mv Antivirais/efeitos adversos
Autoanticorpos/sangue
Complexo de Golgi/imunologia
Hepatite C/sangue
Hepatite C/quimioterapia
Interferon-alfa/efeitos adversos
Polietilenoglicóis/efeitos adversos
Ribavirina/efeitos adversos
Alanina Transaminase/sangue
Antivirais/uso terapêutico
Progressão da Doença
Quimioterapia Combinada
Hepacivirus/genética
Interferon-alfa/uso terapêutico
Humanos
Fígado/patologia
Cirrose Hepática/patologia
Polietilenoglicóis/uso terapêutico
Masculino
Meia-Idade
Proteínas Recombinantes
Ribavirina/uso terapêutico
topic Antivirais/efeitos adversos
Autoanticorpos/sangue
Complexo de Golgi/imunologia
Hepatite C/sangue
Hepatite C/quimioterapia
Interferon-alfa/efeitos adversos
Polietilenoglicóis/efeitos adversos
Ribavirina/efeitos adversos
Alanina Transaminase/sangue
Antivirais/uso terapêutico
Progressão da Doença
Quimioterapia Combinada
Hepacivirus/genética
Interferon-alfa/uso terapêutico
Humanos
Fígado/patologia
Cirrose Hepática/patologia
Polietilenoglicóis/uso terapêutico
Masculino
Meia-Idade
Proteínas Recombinantes
Ribavirina/uso terapêutico
description Faculty of Medicine University Hospital of Bahia. Gastro-Hepatology Unit. Salvador, BA, Brasil
publishDate 2006
dc.date.issued.fl_str_mv 2006
dc.date.accessioned.fl_str_mv 2014-06-30T18:39:42Z
dc.date.available.fl_str_mv 2014-06-30T18:39:42Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv PARANÁ, R. et al. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver International, v. 26, p. 1148-1154, 2006.
dc.identifier.uri.fl_str_mv https://arca.fiocruz.br/handle/icict/7858
dc.identifier.issn.none.fl_str_mv 1478-3223
dc.identifier.doi.none.fl_str_mv 10.1111/j.1478-3231.2006.01345.x
identifier_str_mv PARANÁ, R. et al. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver International, v. 26, p. 1148-1154, 2006.
1478-3223
10.1111/j.1478-3231.2006.01345.x
url https://arca.fiocruz.br/handle/icict/7858
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Blackwell Munksgaard
publisher.none.fl_str_mv Blackwell Munksgaard
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://arca.fiocruz.br/bitstreams/efe7338f-e2ba-49a9-86a9-1ebefd219bfc/download
https://arca.fiocruz.br/bitstreams/30e8dbe5-35b3-4c1a-aa2f-8e90ec5f5e57/download
https://arca.fiocruz.br/bitstreams/e24d1540-02d9-418e-ad22-b9b0534b6cd4/download
https://arca.fiocruz.br/bitstreams/435c7030-ece3-4f29-9e61-1f95a9d6676c/download
bitstream.checksum.fl_str_mv caa0974b7b405828343650aa19017da3
7d48279ffeed55da8dfe2f8e81f3b81f
771fa2a068b1125bf61ec3866e51f1e8
f5a20b37ce866f1c702e27e8adf42dd2
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1839716427458674688

Similar Items